查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1358086

全身麻醉劑市場：依藥物分子、給藥途徑、最終使用者、地區

General Anesthesia Drugs Market, By Drug molecule, By Route of Administration, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 200 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計 2023 年全球全身麻醉劑市場規模將達到 49.5 億美元，預計在預測期內（2023-2030 年）年複合成長率為 4.1%。

報告範圍 報告詳情
基準年 2022年 2023年市場規模 49.5億美元
實績資料 2018-2021 預測期 2023-2030
預測期年複合成長率 4.10% 2030年市場規模預測 65.7億美元
全身麻醉劑的全球市場佔有率(%)（依給藥途徑），2023 年
全身麻醉藥品市場-IMG1

全麻醉劑會抑制大腦層面的感覺、運動、交感神經傳遞，導致患者失去知覺、感覺缺失、無法感受疼痛刺激，同時控制不自主反射，這是一種表現出來的現象。全身麻醉劑有兩種給藥途徑：靜脈麻醉劑（含丙泊酚、依托咪酯、美索比妥、硫噴妥鈉、咪達唑侖和氯胺酮等藥物分子）和吸入麻醉劑（含地氟烷、異氟烷和七氟烷等藥物分子）。主要企業主要致力於修改現有藥物動力學或藥物類別的化學結構，以改善其藥物動力學、藥效學和副作用特性。我們也正在開發可能使用TCI（標靶輸注）的藥物。現有麻醉劑的新應用也在探索中。因此，在市場上引入副作用較少的藥物和有針對性的控制輸注預計將在預測期內推動全球全身麻醉劑市場的成長。

市場動態

藥理學產業的主要參與者致力於改進現有藥物，以開發副作用較少的藥物。例如，2022年7月，全球製藥公司Cosmo Pharmaceuticals宣布，用於靜脈麻醉的新型苯二氮平類藥物BYFAVO已獲得美國食品藥物管理局（FDA）核准用於手術鎮靜和全身核准。藥物（雷馬唑侖）。瑞馬唑侖為超短效藥物，與目前使用的其他苯二氮平類全身麻醉劑相比，鎮靜持續時間短，恢復時間短，長期給藥後蓄積少，副作用少。因此，將此類副作用較少的藥物引入市場有望為製藥商提供開發副作用較少的新藥物的機會。

本研究的主要特點

  • 本報告詳細分析了全球全身麻醉劑市場，並提供了以2022年為基準年的預測期（2023-2030）的市場規模和複合年度（年複合成長率）。它還強調了各個細分市場的潛在收益成長機會，並為該市場說明了一系列有吸引力的投資提案。
  • 它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
  • 它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球全身麻醉劑市場的主要企業。
  • 該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、類型經營團隊、市場擴張和行銷策略做出資訊的決策。
  • 本研究報告針對該產業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
  • 透過用於分析全球全身麻醉劑市場的各種策略矩陣，將有助於相關人員做出決策。

目錄

第1章 調查目的和假設

  • 這項研究的目的
  • 假設
  • 簡稱

第2章 市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、法規及趨勢分析

  • 市場動態
    • 促進因素
    • 抑制因素
    • 市場機會
  • 影響分析
  • 最近的發展
  • 管道分析
  • 配銷通路分析
  • 流行病學
  • 合併、收購和合作
  • 法規場景
  • 主要進展
  • PEST分析

第4章 全球全身麻醉劑市場 - COVID-19 的影響分析

  • 經濟影響
  • 新型冠狀病毒感染疾病（COVID-19）的流行病學
  • 對需求和供給的影響

第5章 全球全身麻醉劑市場：依藥物分子分類，2018-2030

  • 地氟烷
  • 異氟烷
  • 七氟醚
  • 異丙酚
  • 依托咪酯
  • 美索比妥
  • 硫噴妥鈉
  • 咪達唑侖
  • 氯胺酮

第6章 全球全身麻醉劑市場：依給藥途徑分類，2018-2030

  • 靜脈麻醉
  • 吸入麻醉

第7章 全球全身麻醉劑市場：依最終使用者分類，2018-2030 年

  • 醫院
  • 專科診所
  • 門診手術中心

第8章 全球全身麻醉劑市場：依地區分類，2018-2030

  • 北美洲
  • 美國
  • 加拿大
  • 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
  • 中東
  • GCC
  • 以色列
  • 其他中東地區
  • 非洲
  • 北非
  • 中部非洲
  • 南非

第9章 競爭形勢

  • 公司簡介
    • Baxter Healthcare
    • Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

第10章 章

  • 參考
  • 調查方法
簡介目錄
Product Code: CMI524

The global general anesthesia drug market is estimated to be valued at US$ 4.95 Billion in 2023 and is expected to exhibit a CAGR of 4.1% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 4.95 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.10% 2030 Value Projection: US$ 6.57 Bn
Global Anesthesia Drug Market Share (%), By Route of Administration, 2023
General Anesthesia Drugs Market - IMG1

General anesthesia drugs are meant to manifest unconscious patient by the inhibition of sensory, motor, and sympathetic nerve transmission at the level of the brain that results in unconsciousness and lack of sensation and incapable to feel painful stimuli while controlling involuntary reflexes. General anesthesia drugs are administrated by two routes either by intravenous anesthetics that includes drug molecules like propofol, etomidate, methohexital, thiopentone, midazolam and ketamine and other is inhalation anesthetics that includes drug molecules like desflurane, isoflurane, and sevoflurane. The key players are primarily focusing on modifying the chemical structures of existing drugs or drug classes with a direction to improve their pharmacokinetic, pharmacodynamics, and side effect properties. Furthermore, they are developing drugs that have possibilities of using Target Controlled Infusion (TCI). The new applications of pre-existing anesthetic drugs are being explored. Thus, the introduction of such drugs with lesser side effects and target controlled infusion in the market are expected to drive the growth of the global general anesthesia drugs market over the forecast period.

Market Dynamics

The key players in the pharmacology industry are focusing on the development of drugs with lesser side effects by the modification of preexisting drugs. For instance, in July 2022, Cosmo pharmaceuticals, a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved BYFAVO (Remimazolam), a novel benzodiazepine for intravenous anesthetics approved for use as procedural sedation and general anesthesia. It has an ultra-short duration of action and it uses target controlled infusion with short and expected duration of sedative action, short recovery time, rare accumulation after long-term infusion, and lesser side effects as compared to those of other currently used Benzodiazepines molecule of general anesthesia drugs. Thus, the introduction of such drugs with lesser side effects in the market is expected offer opportunities for drug manufacturers to develop more novel drugs with lesser side effects.

Key features of the study:

  • This report provides an in-depth analysis of the global general anesthetic drug market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year. It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global general anesthetic drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • The key companies covered as a part of this study include Baxter Healthcare, Dr. Reddy's Laboratories, Fresenius Kabi, Pfizer Inc., Hikma Pharmaceuticals, Sagent Pharmaceuticals, Teva Pharmaceuticals, Par Pharmaceutical, Viatris Inc., AbbVie, Piramal Critical Care, Aspen Global Incorporated, B. Braun SE, Abbott, COSMO PHARMACEUTICALS, Hospira Inc., Maruishi, Hengrui, and Lunan
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global general anesthetic drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global general anesthetic drug market.

Detailed Segmentation:

  • Global General Anesthesia Drugs Market, By Drug molecule:
    • Desflurane
    • Isoflurane
    • Sevoflurane
    • Propofol
    • Etomidate
    • Methohexital
    • Thiopentone
    • Midazolam
    • Ketamine
  • Global General Anesthesia Drugs Market, By Route of Administration:
    • Intravenous Anesthesia
    • Inhalation Anesthesia
  • Global General Anesthesia Drugs Market, By End User:
    • Hospital
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Global General Anesthesia Drugs Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles
    • Baxter Healthcare
    • Dr. Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Molecule
    • Market Snippet, By Route of Administration
    • Market Snippet, By End User
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Development
  • Pipeline Analysis
  • Distribution Channel Analysis
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global General Anesthesia Drug Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global General Anesthesia Drug Market , By Drug Molecule, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Desflurane
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Isoflurane
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Propofol
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Etomidate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Etomidate
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Thiopentone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Midazolam
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Ketamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

6. Global General Anesthesia Drug Market , By Route of Administration, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Intravenous Anesthesia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends
  • Inhalation Anesthesia
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
    • Segment Trends

7. Global General Anesthesia Drug Market , By End User, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospital
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

8. Global General Anesthesia Drug Market , By Region, 2018 - 2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.S.
  • Canada
  • Europe
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast,Y-o-Y Growth and By Drug Molecule, 2018 -2030, (US$ Bn)
    • Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast,Y-o-Y Growth and By End User, 2018 - 2030, (US$ Bn)
    • Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • Baxter Healthcare
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Overview
  • Strategies
    • Reddy's Laboratories
    • Novartis International AG
    • Hospira
    • Maruishi
    • Hengrui
    • Lunan
    • Fresenius Kabi
    • Pfizer Inc.
    • Hikma Pharmaceuticals
    • Sagent Pharmaceuticals
    • Teva Pharmaceuticals
    • Par Pharmaceutical
    • Viatris Inc.
    • AbbVie
    • Piramal Critical Care
    • Aspen Global Incorporated
    • B. Braun SE
    • Abbott
    • Cosmo pharmaceuticals

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact